Fig. 3From: Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn’s disease: a Chinese real-world studyReceiver-operating curve analysis for endoscopic remission based on UST trough concentration with optimal UST trough level cut-off of 1.12 μg/mLBack to article page